Global Disparities in Hepatitis B Elimination-A Focus on Africa

Viruses. 2022 Jan 3;14(1):82. doi: 10.3390/v14010082.

Abstract

In 2016, WHO member states at the World Health Assembly adopted a Global Health Sector Strategy that included a policy of eliminating viral hepatitis. Clear targets were established to assist in achieving this by 2030. The strategy, while achievable, has exposed existing global disparities in healthcare systems and their ability to implement such policies. Compounding this, the regions with most disparity are also those where the hepatitis B prevalence and disease burden are the greatest. Foundational to hepatitis B elimination is the identification of both those with chronic infection and crucially pregnant women, and primary prevention through vaccination. Vaccination, including the birth dose and full three-dose coverage, is key, but complete mother-to-child transmission prevention includes reducing the maternal hepatitis B viral load in the third trimester where appropriate. Innovations and simplified tools exist in order to achieve elimination, but what is desperately required is the will to implement these strategies through the support of appropriate investment and funding. Without this, disparities will continue.

Keywords: Hep B birth dose; disparities; elimination; integration; triple elimination; vaccination; viral hepatitis.

Publication types

  • Review

MeSH terms

  • Africa / epidemiology
  • Antiviral Agents / therapeutic use
  • Cost of Illness
  • Female
  • Global Health*
  • Healthcare Disparities*
  • Hepatitis B / drug therapy
  • Hepatitis B / epidemiology
  • Hepatitis B / prevention & control*
  • Hepatitis B / transmission
  • Hepatitis B Vaccines
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / epidemiology
  • Hepatitis B, Chronic / prevention & control*
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control
  • Prevalence
  • Vaccination

Substances

  • Antiviral Agents
  • Hepatitis B Vaccines